Novartis Teams With Pear Therapeutics In Neurological Digital Health Pact

 
• By Sten Stovall

Duo aims to get Pear's THRIVE digital therapeutic approved, and to develop a new application to treat MS patients, then seek validation in clinical studies.

Digital screen
Duo Will Develop Clinically-Validated Software Used for Schizophrenia and MS • Source: Shutterstock

More from Drug Pricing

More from Scrip